Updated 02:01 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,876.40 -0.25% CL 88.33 -0.26% BTC 64,613.34 +0.76%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,876 −0.25% BTC $64,613 +0.76% VIX 19.30 +3.21% latest tape · as of 02:01 UTC
The Screen · Financials · Shell Companies

Calithera Biosciences, Inc.

CALA · PNK · USD · 8 employees

Calithera Biosciences, Inc.

FAIL · Does not pass the screen
0.00 USD

Price as of 10 Nov 2026Daily close, not a live quoteLast reviewed 6 days ago

Screened 2026-11-10 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price0.00 USD at the 10 Nov 2026 close
  • Fair valueUnder review: our model has no usable estimate for it yet.
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed10 Nov 2026 (6 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-10).

Current read
Accumulation ?
Screened · screened 2026-11-10
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price0.00 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Accumulation0.00-66.7% to today First review on file: Accumulation

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Calithera Biosciences, Inc. holds its Accumulation at $0.00. Consolidating, no directional conviction, held for 2 days.

As held on the ledger · 2026-11-10
PhaseAccumulation
Quantitative stateConsolidating, no directional conviction, held for 2 days
Price at the screen$0.00
ValuationN/A trailing · 0.00 forward price to earnings
Values screenFAIL · score 70.0
Beta-1.29
The Workings

Five Screens, Shown in Full

Does not pass. Business activity: conventional financial services

TestFigureLimitWhat it meansStatus
Business activity Excluded Core business clean Its core business involves an activity the values screen does not clear. Fail
Debt load 68,390.80% Below 33% Interest-bearing debt is 68,390.8% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 1,044,786.54% Below 33% Interest-bearing cash and securities are 1,044,786.5% of assets, above the one-third limit. Fail
Receivables 0.00% Below 49% Money owed to the company is 0.0% of assets, under the 49% limit. Pass
Revenue purity 3.54% Below 5% Only 3.5% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Calithera Biosciences, does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.

Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when CALA's ethical verdict changes

Today CALA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model has no usable estimate for it yet. We show no fair value, margin of safety or value read built on it until the review clears.

How a fair value is estimated: discounted cash flow (DCF).

Price History & Projections

Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-10 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E0.0x
EPS, trailing-3.97
EPS, forward-1.35
Return on equity-114.1%not currently earning a positive return on equity
Debt to equity0.08minimal debt: a conservative balance sheet
Current ratio3.60comfortably covers its short-term bills
Beta-1.29barely tracks the market's swings
Short interest, float0.09%
52-week range0.00 - 0.00
Employees8

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

CALA trades on PNK. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-05 Accumulation $0.00 +0.0% Entry 8

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 85%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-10-25 Accumulation $0.00 +0.0% Entry 7

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 85%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-10-11 Accumulation $0.00 -66.7% Entry 6

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 66.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 85%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-08-24 Accumulation $0.00 +0.0% Entry 5

Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 85%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-07-24 Accumulation $0.00 +0.0% Entry 4

Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 85%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-07-18 Accumulation $0.00 +0.0% Entry 3

Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 85%. Our forward projection puts the odds of a 10% gain over the next month near 2%.

2026-07-03 Accumulation $0.00 +0.0% Entry 2

Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.

2026-07-02 Accumulation $0.00 Entry 1

Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $0.00 +200.0% · $3,000 +200.0%
2 months $0.00 +0.0% · $1,000 +0.0%
3 months $0.00 +0.0% · $1,000 +0.0%
6 months $0.00 +200.0% · $3,000 +200.0%
1 year $0.00 -85.0% · $150 -85.0%
2 years $0.02 -98.5% · $15 -98.5%
3 years $0.35 -99.9% · $1 -99.9%
5 years $46.40 -100.0% · $0 -100.0%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever CALA does next, these words stay.

Calithera Biosciences, Inc. · CALA · Accumulation · $0.00
Recorded 2026-11-10 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.